Physician profile
Mingchen Song
NPI 1659571487
$9,823.00
in general payments reported to CMS, 2019-2025
14 companies · $8,334 in 2025
The $8,334 reported for 2025 was more than what 92% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $195 · 2020: $89.38 · 2021: $129 · 2022: $138 · 2023: $310 · 2024: $627 · 2025: $8,334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $7,000 · Food and Beverage: $1,298 · Travel and Lodging: $974.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $7,000.00 |
| Food and Beverage | $1,298.49 |
| Travel and Lodging | $973.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $8,053.86 | 2025 | |
| Glaxosmithkline, LLC. | $440.60 | 2020-2025 | Nucala, Trelegy Ellipta |
| Noah Medical Corporation | $367.74 | 2024 | Galaxy |
| Astrazeneca Pharmaceuticals LP | $287.60 | 2019-2023 | Airsupra, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $183.46 | 2021-2025 | Ofev, Jascayd |
| Janssen Pharmaceuticals, INC | $109.25 | 2019 | |
| Mylan Specialty L.P. | $98.36 | 2022-2024 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $63.05 | 2024-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $49.80 | 2019 | |
| Grifols USA, LLC | $43.39 | 2020-2022 | |
| Genzyme Corporation | $42.54 | 2024-2025 | |
| Boston Scientific Corporation | $40.16 | 2022 | |
| Viatris Specialty LLC | $23.93 | 2025 | Yupelri |
| Insmed, INC. | $19.26 | 2025 | Brinsupri, Arikayce |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mingchen Song listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.